{"id":"NCT00782340","sponsor":"Chelsea Therapeutics","briefTitle":"A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa","officialTitle":"Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-10-31","resultsPosted":"2014-05-16","lastUpdate":"2014-05-16"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Symptomatic Neurogenic Orthostatic Hypotension (NOH)","Non-diabetic Neuropathy","Primary Autonomic Failure","Dopamine Beta Hydroxylase Deficiency"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Droxidopa","otherNames":[]}],"arms":[{"label":"Droxidopa","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.","primaryOutcome":{"measure":"Change in Orthostatic Hypotension Questionnaire Score (OHQ)","timeFrame":"7 days","effectByArm":[{"arm":"Droxidopa","deltaMin":-1.83,"sd":2.067},{"arm":"Placebo","deltaMin":-0.93,"sd":1.691}],"pValues":[{"comp":"OG000 vs OG001","p":"0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":26},"locations":{"siteCount":21,"countries":["United States","Canada"]},"refs":{"pmids":["28494751","27538531"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":263},"commonTop":["Headache","Dizziness"]}}